1003 related articles for article (PubMed ID: 27413154)
1. A New Glucocerebrosidase Chaperone Reduces α-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism.
Aflaki E; Borger DK; Moaven N; Stubblefield BK; Rogers SA; Patnaik S; Schoenen FJ; Westbroek W; Zheng W; Sullivan P; Fujiwara H; Sidhu R; Khaliq ZM; Lopez GJ; Goldstein DS; Ory DS; Marugan J; Sidransky E
J Neurosci; 2016 Jul; 36(28):7441-52. PubMed ID: 27413154
[TBL] [Abstract][Full Text] [Related]
2. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
[TBL] [Abstract][Full Text] [Related]
3. A characterization of Gaucher iPS-derived astrocytes: Potential implications for Parkinson's disease.
Aflaki E; Stubblefield BK; McGlinchey RP; McMahon B; Ory DS; Sidransky E
Neurobiol Dis; 2020 Feb; 134():104647. PubMed ID: 31669751
[TBL] [Abstract][Full Text] [Related]
4. Glucocerebrosidase and its relevance to Parkinson disease.
Do J; McKinney C; Sharma P; Sidransky E
Mol Neurodegener; 2019 Aug; 14(1):36. PubMed ID: 31464647
[TBL] [Abstract][Full Text] [Related]
5. Acid ceramidase involved in pathogenic cascade leading to accumulation of α-synuclein in iPSC model of GBA1-associated Parkinson's disease.
Kumar M; Srikanth MP; Deleidi M; Hallett PJ; Isacson O; Feldman RA
Hum Mol Genet; 2023 May; 32(11):1888-1900. PubMed ID: 36752535
[TBL] [Abstract][Full Text] [Related]
6. Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies.
Sardi SP; Clarke J; Viel C; Chan M; Tamsett TJ; Treleaven CM; Bu J; Sweet L; Passini MA; Dodge JC; Yu WH; Sidman RL; Cheng SH; Shihabuddin LS
Proc Natl Acad Sci U S A; 2013 Feb; 110(9):3537-42. PubMed ID: 23297226
[TBL] [Abstract][Full Text] [Related]
7. Potential Binding Sites of Pharmacological Chaperone NCGC00241607 on Mutant β-Glucocerebrosidase and Its Efficacy on Patient-Derived Cell Cultures in Gaucher and Parkinson's Disease.
Kopytova AE; Rychkov GN; Cheblokov AA; Grigor'eva EV; Nikolaev MA; Yarkova ES; Sorogina DA; Ibatullin FM; Baydakova GV; Izyumchenko AD; Bogdanova DA; Boitsov VM; Rybakov AV; Miliukhina IV; Bezrukikh VA; Salogub GN; Zakharova EY; Pchelina SN; Emelyanov AK
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240451
[TBL] [Abstract][Full Text] [Related]
8. Macrophage models of Gaucher disease for evaluating disease pathogenesis and candidate drugs.
Aflaki E; Stubblefield BK; Maniwang E; Lopez G; Moaven N; Goldin E; Marugan J; Patnaik S; Dutra A; Southall N; Zheng W; Tayebi N; Sidransky E
Sci Transl Med; 2014 Jun; 6(240):240ra73. PubMed ID: 24920659
[TBL] [Abstract][Full Text] [Related]
9. Novel beta-glucocerebrosidase chaperone compounds identified from cell-based screening reduce pathologically accumulated glucosylsphingosine in iPS-derived neuronal cells.
Naito Y; Sakamoto S; Kojima T; Homma M; Tanaka M; Matsui H
SLAS Discov; 2023 Oct; 28(7):344-349. PubMed ID: 37369311
[TBL] [Abstract][Full Text] [Related]
10. A new glucocerebrosidase-deficient neuronal cell model provides a tool to probe pathophysiology and therapeutics for Gaucher disease.
Westbroek W; Nguyen M; Siebert M; Lindstrom T; Burnett RA; Aflaki E; Jung O; Tamargo R; Rodriguez-Gil JL; Acosta W; Hendrix A; Behre B; Tayebi N; Fujiwara H; Sidhu R; Renvoise B; Ginns EI; Dutra A; Pak E; Cramer C; Ory DS; Pavan WJ; Sidransky E
Dis Model Mech; 2016 Jul; 9(7):769-78. PubMed ID: 27482815
[TBL] [Abstract][Full Text] [Related]
11. Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease.
Horowitz M; Braunstein H; Zimran A; Revel-Vilk S; Goker-Alpan O
Adv Drug Deliv Rev; 2022 Aug; 187():114402. PubMed ID: 35764179
[TBL] [Abstract][Full Text] [Related]
12. Properties of neurons derived from induced pluripotent stem cells of Gaucher disease type 2 patient fibroblasts: potential role in neuropathology.
Sun Y; Florer J; Mayhew CN; Jia Z; Zhao Z; Xu K; Ran H; Liou B; Zhang W; Setchell KD; Gu J; Grabowski GA
PLoS One; 2015; 10(3):e0118771. PubMed ID: 25822147
[TBL] [Abstract][Full Text] [Related]
13. Direct targeting of wild-type glucocerebrosidase by antipsychotic quetiapine improves pathogenic phenotypes in Parkinson's disease models.
Burbulla LF; Zheng J; Song P; Jiang W; Johnson ME; Brundin P; Krainc D
JCI Insight; 2021 Oct; 6(19):. PubMed ID: 34622801
[TBL] [Abstract][Full Text] [Related]
14. Glucocerebrosidase, a new player changing the old rules in Lewy body diseases.
Yang NY; Lee YN; Lee HJ; Kim YS; Lee SJ
Biol Chem; 2013 Jul; 394(7):807-18. PubMed ID: 23435096
[TBL] [Abstract][Full Text] [Related]
15. Glucocerebrosidase deficiency in dopaminergic neurons induces microglial activation without neurodegeneration.
Soria FN; Engeln M; Martinez-Vicente M; Glangetas C; López-González MJ; Dovero S; Dehay B; Normand E; Vila M; Favereaux A; Georges F; Lo Bianco C; Bezard E; Fernagut PO
Hum Mol Genet; 2017 Jul; 26(14):2603-2615. PubMed ID: 28520872
[TBL] [Abstract][Full Text] [Related]
16. Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance.
Blanz J; Saftig P
J Neurochem; 2016 Oct; 139 Suppl 1():198-215. PubMed ID: 26860955
[TBL] [Abstract][Full Text] [Related]
17. The Complicated Relationship between Gaucher Disease and Parkinsonism: Insights from a Rare Disease.
Aflaki E; Westbroek W; Sidransky E
Neuron; 2017 Feb; 93(4):737-746. PubMed ID: 28231462
[TBL] [Abstract][Full Text] [Related]
18. Gaucher-related synucleinopathies: the examination of sporadic neurodegeneration from a rare (disease) angle.
Sardi SP; Cheng SH; Shihabuddin LS
Prog Neurobiol; 2015 Feb; 125():47-62. PubMed ID: 25573151
[TBL] [Abstract][Full Text] [Related]
19. A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy.
Cosden M; Jinn S; Yao L; Gretzula CA; Kandebo M; Toolan D; Hatcher NG; Ma L; Lemaire W; Adam GC; Burlein C; Minnick C; Flick R; Watt ML; Mulhearn J; Fraley M; Drolet RE; Marcus JN; Smith SM
Neurobiol Dis; 2021 Nov; 159():105507. PubMed ID: 34509608
[TBL] [Abstract][Full Text] [Related]
20. A modulator of wild-type glucocerebrosidase improves pathogenic phenotypes in dopaminergic neuronal models of Parkinson's disease.
Burbulla LF; Jeon S; Zheng J; Song P; Silverman RB; Krainc D
Sci Transl Med; 2019 Oct; 11(514):. PubMed ID: 31619543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
